Peptic Ulcer Drugs Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (H2 receptor Antagonists, Proton Pump Inhibitors (PPIs), Antacids, Ulcer Protective Drugs, Potassium-Competitive Acid Blockers (P-CAB), Antibiotics, Others), By Formulation (Oral tablets, Effervescent Tablets, Effervescent Granules, Syrups, Injections), By Application (Gastroesophagal Reflux Disease (GERD), Gastritis, Duodenal Ulcers, Gastric Ulcers, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region Forecast 2019-2030

Peptic Ulcer Drugs Market size was valued at US$ 5,070 million in 2023 and is poised to grow at a CAGR of 4.1% from 2024-2030. Peptic ulcers are open sores that form on the lining of the stomach, upper small intestine, or esophagus and are often brought on by the erosion of the protective mucous layer due to an overabundance of gastric acid output or an infection with the bacterium Helicobacter pylori. Peptic ulcers may produce a number of symptoms, including bloating, nausea, vomiting, and stomach discomfort, and if left untreated, they can lead to complications such as bleeding, perforation, and blockage of the digestive tract. Drugs for peptic ulcers are intended to treat gastric ulcers, duodenal ulcers, gastro-oesophageal reflux disease (GORD) and prevent subsequent problems. Peptic ulcers are a common gastrointestinal disorder affecting millions of people worldwide. The high prevalence of peptic ulcers drives the demand for effective drugs for their treatment, ultimately aiding in the growth of the market.

According to a research study, four million individuals worldwide suffer from peptic ulcer disease (PUD) each year, with a lifetime prevalence of 5–10% in the general population. Moreover, technological advancements in drug formulations along with rising healthcare expenditure drive the peptic ulcer drugs market as well as create significant opportunities to develop new solutions to treat peptic ulcers such as innovative delivery systems like controlled-release formulations or targeted drug delivery and novel drug formulation, such as combination therapies.

However, side effects and safety concerns are posing challenges to the growth of the peptic ulcers market. Various pharmaceutical companies are adapting their strategies to develop innovative products and meet the changing demands of patients and healthcare systems worldwide. For instance, in April 2023, Akums Drugs and Pharmaceutical launched Combikit for the treatment of Duodenal Ulcer and H. pylori infection.

Key Developments:

• In August 2022, the peptic ulcer drug Dartisla ODT manufactured by Edenbridge Pharmaceuticals received FDA approval.
• In August 2021, Dr Reddy's Laboratories launched generic Chlordiazepoxide Hydrochloride and Clidinium Bromide capsules for the treatment of stomach ulcers, irritable bowel syndrome, and inflammation of the colon, in the US market.